Compare · WST vs XAGE
WST vs XAGE
Side-by-side comparison of West Pharmaceutical Services Inc. (WST) and Longevity Health Holdings Inc. (XAGE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both WST and XAGE operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST carries a market cap of $25.38B.
- Over the past year, WST is up 64.2% and XAGE is down 44.4% - WST leads by 108.6 points.
- WST has hit the wire 6 times in the past 4 weeks while XAGE has been quiet.
- WST has more recent analyst coverage (18 ratings vs 0 for XAGE).
- Company
- West Pharmaceutical Services Inc.
- Longevity Health Holdings Inc.
- Price
- $359.26+1.91%
- $2.32-15.02%
- Market cap
- $25.38B
- -
- 1M return
- +9.55%
- +0.00%
- 1Y return
- +64.20%
- -44.36%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 6
- 0
- Recent ratings
- 18
- 0
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest WST
- West Declares Quarterly Dividend
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- BNP Paribas Exane initiated coverage on West Pharm with a new price target
- West to Host Second-Quarter 2026 Conference Call
- SEC Form 4 filed by Director Haugen Janet Brutschea
- West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System
- West Pharm upgraded by Barclays with a new price target
- Wolfe Research resumed coverage on West Pharm with a new price target
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- West Appoints Michel Lagarde to be President and Chief Executive Officer
Latest XAGE
- Longevity Health Holdings Inc. filed SEC Form 8-K: Leadership Update
- SEC Form 424B3 filed by Longevity Health Holdings Inc.
- SEC Form SCHEDULE 13D filed by Longevity Health Holdings Inc.
- SEC Form 4 filed by Ajjarapu J. Ram
- SEC Form 3 filed by new insider Ajjarapu J. Ram
- SEC Form 424B3 filed by Longevity Health Holdings Inc.
- SEC Form 10-K filed by Longevity Health Holdings Inc.
- Longevity Health Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Longevity Health Holdings Closes Strategic Investment and Appoints Ram Ajjarapu as Chairman and CEO to Drive Acquisition-Focused Growth
- SEC Form 424B3 filed by Longevity Health Holdings Inc.